Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
|Videos|July 23, 2021
Dr. Zillioux discusses same-day discharge for FPMRS procedures
Author(s)Urology Times staff
"Same-day discharge is safe and feasible across a broad spectrum of FPMRS cases," says Jacqueline Zillioux, MD.
Advertisement
In this video, Jacqueline Zillioux, MD, discusses the recent Neurourology & Urodynamics paper, “Same-day discharge across FPMRS surgical cases is safe and feasible: A 10-year single-surgeon experience.” Zillioux is a urology FPMRS fellow at Cleveland Clinic.
Advertisement
Related to this article
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Factors shaping PSMA-PET agent selection in prostate cancer
2
Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC
3
Chad Ritch, MD, on using PSMA-PET to guide treatment decisions
4
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
5